Menu
Enrolling by invitation NCT06833125

The Prophylactic Effect of Garlic Tablets to Prevent Nosocomial Infections in Intensive Care Unit Patients.

Phase III Interventional Nosocomial Infection

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Garlic powder standardized to allicin.
Who it may be relevant to
Registry conditions: Nosocomial Infection. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The goal of this clinical trial is to learn if garlic tablets works to prevent nosocomial infections in hospitalized patients in ICU. The main questions it aims to answer are: Does garlic tablets administration lower the occurence of nosocomial infections in hospitalized patients in ICU?

Interventions

  • Drug Garlic powder standardized to allicin
    The intervention is the administration of garlic tablets (Tomex plus 300 mg) two tablets twice daily (which contains 5.4 mg allicin the active ingredient with anibacterial effect) for 6 days just after ICU admission

Primary outcome measures

  • Occurrence of central line-associated bloodstream infections, catheter- associated urinary tract infections, surgical site infections and ventilator- associated pneumonia in the two groups (by cultures results). [Time frame: one year]
Secondary outcome measures (2)
  • Values of Blood white cell count, body temperature and C-reactive protein of the patient in the two groups . [Time frame: one year]
  • Values of Blood white cell count, body temperature and C-reactive protein of the patient in the two groups . [Time frame: one year]

Eligibility criteria

Inclusion criteria

  • All patients aged from 18 to 65 years old admitted to intensive care units without any type of infection.

Exclusion criteria

  • Patients with signs /symptoms of infection.
  • Patients with human immunodeficiency virus, malignancy and patients with a history of recent immunosuppressants or corticosteroids administration.
  • Patients with bleeding disorders or abnormal coagulation profile
  • Patients who will planned for surgery within 2 weeks.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Prevention

Study locations

Egypt · 1 center
  • Alexandria Main University Hospital — Alexandria

Identifiers

NCT: NCT06833125 · 0108752

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗